摘要
目的探讨心神宁联合氟哌噻吨美利曲辛片治疗心脏神经官能症(CN)的临床疗效及安全性。方法选取内蒙古精神卫生中心2013年7月—2015年7月收治的CN患者206例,随机分为单药组和联合组,各103例。单药组患者入院后给予氟哌噻吨美利曲辛片治疗,联合组患者在单药组基础上加服心神宁,两组患者均持续治疗3个月。比较两组患者治疗前后Zung抑郁自评量(SDS)评分及焦虑自评量表(SAS)评分、临床疗效、不良反应及疾病复发情况。结果治疗前,两组患者SAS评分、SDS评分比较,差异无统计学意义(P>0.05);治疗后,联合组患者SAS评分、SDS评分低于单药组(P<0.05)。联合组患者临床疗效优于单药组(P<0.05)。两组患者均未出现明显不良反应。随访1年,联合组患者复发率低于单药组(P<0.05)。结论心神宁联合氟哌噻吨美利曲辛片治疗CN临床疗效确切,可有效缓解患者焦虑、抑郁程度,降低复发率,且安全性好。
Objective To investigate the clinical effect and the safety of xinshenning combined with flupentixol and melitracen tablets in treating cardiac neurosis（ CN）. Methods A total of 206 cases of patients with CN were selected from July 2013 to July 2015 in Inner Mongolia Spiritual Health Center,which were randomly divided into single drug group and combination group,103 cases in each group. The single drug group was treated with flupentixol and melitracen tablets,combination group was treated with xinshenning based on single drug group,both groups were treated for 3 months. The SAS and SDS scores before and after treatment,clinical effect and the incidence of adverse reactions,recurrence rate were compared between the two groups. Results Before treatment,no statistically significant differences in SAS scores or SDS scores was found between the two groups（ P〉0. 05）; after treatment,the SAS scores and SDS scores of combination group were lower than single drug group（ P〈0. 05）. The combination group of clinical effect was better than single drug group（ P〈0. 05）. No obvious adverse reactions occurred between the two groups. Followed-up for 1 year,the recurrence rate of combination group was lower than single drug group（ P〈0. 05）. Conclusion Xinshenning combined with flupentixol and melitracen tablets have an exactly clinical effect in treating CN,it can effectively relieve the anxiety and depression of patients,reduce the recurrence rate,and with good safety.
出处
《临床合理用药杂志》
2017年第9期24-25,28,共3页
Chinese Journal of Clinical Rational Drug Use
